drugset / Trial / NCT01830556

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01830556 ↗

Phase 2 Unknown 120 enrolled Karolinska University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary To investigate in patients with relapsed or metastatic squamous cell carcinoma of the head and neck whether progression free survival (PFS) in the arm with cetuximab, paclitaxel and carboplatin based chemotherapy is not markedly worse than PFS in the arm with cetuximab and 5-FU, cisplatin or carboplatin based chemotherapy. Secondary To compare in patients with relapsed or metastatic squamous cell carcinoma of the head and neck the following study variables between both treatment arms: * Best overall response * Duration of response * Time to treatment failure * Overall survival * Safety

Timeline

Start
2011-11
Primary completion
2013-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 500 mg/m2 Intravenous